Biomedical subjects

F Feng

Publications and source records attributed to F Feng.

At least 37 records · Page 2Linked to original sources

PubMed2000

[Nasea injection in the prophylaxis of gastrointestinal reaction induced by chemotherapeutic agents].

OBJECTIVE: To evaluate the efficacy and side effects of nasea injection for the prophylaxis of gastrointestinal reactions induced by chemotherapeutic agents, and compare them with those of kytril. METHODS: A multicenter, open, randomized self-crossover control trial was carried out. All the eligible patients were randomized into AB or BA group. The patients in AB group were treated by nasea in the first cycle and kytril in the second cycle, those in BA group were treated with the drugs in the reverse order. RESULTS: In patients enrolled in this study, 98 patients were evaluable for response, including 61 patients in DDP-arm and 37 in ADM-arm. Nasea was as effective as kytril in the control of anorexia, nausea and vomiting in the 0-6 hour period after chemotherapy. Nasea was significantly superior to kytril in the complete control of anorexia (38.8% vs 25.5%, P < 0.05) in the 0-24 hour period. The overall control rate of nausea by nasea in the 0-12, 0-18, and 0-24 hour period was 73.6%, 71.4%, 67.3%, respectively, which was significantly higher than that by kytril (65.3%, 61.2%, 48%). Nevertheless, in the control of vomiting in the 0-24 hour period, no statistical difference between the two drugs was observed. Nasea and kytril were equally effective in the control of anorexia, nausea and vomiting induced by DDP and ADM. The side effects of nasea were head heaviness, headache, dry mouth and constipation, etc. All of these were mild and comparable with kytril in their frequencies. CONCLUSION: Nasea can effectively prevent the gastrointestinal reaction induced by chemotherapeutic agents. The side effects of nasea are similar to those of kytril but its effect to alleviate gastrointestinal reactions is of longer duration.

Adolescent↗

PubMed2000

[Treatment of advanced Hodgkin's disease: an analysis of 128 cases].

OBJECTIVE: To explore the rational treatment for advanced Hodgkin's disease. METHODS: A total of 128 patients with advanced Hodgkin's disease was included in this study. They could be divided into 3 groups according to the treatment they received. Patients in group 1 (n = 99) were treated by combination chemotherapy plus radiotherapy. Patients in group 2 (n = 24) were treated by chemotherapy alone. The remaining 5 patients in group 3 were treated by radiotherapy alone. The chemotherapeutic regimens used were MOPP, MOPP alternating with CHOP, or with ABVD. RESULTS: The overall response rate of 127 evaluable patients was 96.1%. The overall 1-, 3-, 5, and 10-year survival rate was 91.4%, 70.3%, 56.8% and 52.4%, respectively. The complete response (CR) rate in the 3 groups of patients was 69.7%, 58.3% and 100%, respectively. Patients in clinical stage III with no bulky mass, no systemic symptoms, and their tumor was predominantly of lymphocytic or nodular sclerotic type had better long term survival than those in clinical stage IV with bulky mass, systemic symptoms, and with lymphocyte depleting, mixed cellular tumor. Better long term survival was seen in patients who showed complete response to combined chemotherapy and radiotherapy. At least 6 cycles of chemotherapy were needed. CONCLUSION: Combination chemotherapy plus radiotherapy is effective in the treatment of advanced Hodgkin's disease.

Adolescent↗

PubMed2000

[Simultaneous determination of fluoroacetamide and tetramethylendisulfotetramin with gas chromatography-mass spectrography].

Simultaneous determination of fluoroacetamide and tetramethylendisulfotetramin with gas chromatography-mass spectrography was established. The condition of separation, ways of extraction, the qualitative and quantitative determination of two compounds were discussed. The linear ranges of fluoroacetamide and tetramethylendisulfotetramin were 5-40 micrograms/ml and 0.5-20.0 micrograms/ml, respectively. The recoveries of these two compounds in different sample were 52.25%-94.30% and 61.85%-92.50%, respectively. The method was fast, sensitive and accurate.

Bridged-Ring Compounds↗

PubMed1999

The clinical and epidemiological significance of serum PreS1/anti-PreS1 in HBV infection.

OBJECTIVE: To investigate whether PreS1 antigen and/or anti-PreS1 antibody in serum might have some significance different from routine hepatitis B virus (HBV) markers in hepatitis B virus infection. METHODS: Forty-six acute hepatitis B patients and 377 chronic persistent hepatitis patients were examined to assess the clinical significance of serum PreS1/anti-PreS1. HBV family clustering analysis was carried out in a village in Shanghai suburb area, and case-control study on role of PreS1 in HBV spreading was undertaken in Tangshan, Hebei province. RESULTS: PreS1 in HBsAg positive sera from chronic persistent hepatitis patients correlated with HBV DNA (P < 0.05), while the presence of PreS2 in HBsAg positive sera was much more common than that of PreS1 and had no correlation with HBeAg or HBV DNA. Among 46 patients with acute hepatitis B, the appearance of anti-PreS1 antibody in serum correlated with the disappearing or decreasing of both PreS1 and ALT. In antiviral treatment, PreS1 antigen turned negative much earlier than PreS2 and HBsAg in acute hepatitis B patients' sera. Family clustering analysis suggested that people with PreS1 positive in serum were more infective than those with HBsAg positive alone (P < 0.01). The case-control study showed that chronic hepatitis B patients with PreS1 positive in serum played a much more important role in HBV spreading than those with PreS1 negative (P < 0.01) and asymptomatic HBsAg carriers (P < 0.01), and the odds ratios (OR) were 3.8 and 3.2, respectively. CONCLUSIONS: Serum PreS1 closely correlates with active virus replication, and PreS1/anti-PreS1 status indicates the outcome of acute hepatitis B. The serum PreS1/anti-PreS1 marker is of some significance in HBV epidemiology as well.

Biomarkers↗

PubMed1999

[Adrenal metastasis in primary lung cancer].

OBJECTIVE: To study the incidence, histologic types, clinical symptoms, response rates, and median survival time of adrenal metastasis in primary lung cancer. METHODS: The clinical data were retrospectively evaluated in 96 out of 6,976 patients with adrenal metastasis in primary lung cancer between January 1984 and January 1997. RESULTS: The incidence of adrenal metastasis was 1.38% (96/6,976) in 6,976 patients, 2.25% (37/1,643) in small cell lung cancer, 1.11% (59/5333) in non-small cell lung cancer. Abdominal pain and lumbago (excluding other reasons, for example, abdominal vertebrae and other abdominal organs were involved) occurred in 39% (37/96) in 96 patients. A overall response rate (CR + PR) was 43% in 54 patients who received chemotherapy (5 patients combined with irradiation) and could be evaluated. A median survival time was 7.17 (1-20) months in 96 patients. CONCLUSIONS: Primary lung cancer is easy to spread to adrenals. The incidence of adrenal metastasis is related to histologic types of primary lung cancer. Clinical symptoms include abdominal pain and lumbago. Surgical resection may be applied for a solitary adrenal metastasis after the primary tumor is removed. Chemotherapy is effective for patients with adrenal metastasis synchronous with other sites metastasis. The palliative radiation therapy can produce a high response rate in pain relief.

Adrenal Gland Neoplasms↗

PubMed1999

[Expression of multidrug resistance-associated protein in human non-small cell lung cancer].

OBJECTIVE: To investigate the expression of the multidrug resistance-associated protein(MRP) gene and MRP in human non-small-cell lung cancer tissues and to determine whether such expression was related to cell type, differentiation, tumour size, lymph node metastasis and prognosis. METHODS: 92 paraffin-embeded lung tumor samples (43 squamous cell carcinoma, 49 adenocarcinoma) and 16 fresh non-small-cell lung cancer samples were examined by using immunohistochemistry method and the reverse transcription-polymerase chain reaction (RT-PCR) technology respectively. RESULTS: The expression of MRP mRNA and MRP were detectable in 31% (5-16) and 54% (50/92) of non-small-cell lung cancer specimens respectively. Eighteen(42%) squamous cell carcinoma specimens and thirty-two(65%) adenocarcinoma specimens showed positive immunostaining for MRP(P < 0.05). The expression of MRP was not related to tumour size, lymph node metastasis and cell differentiation significantly(P > 0.05). The five-year survival rate after operation of patients with MRP-positive tumours and MRP-negative tumours were 16% (8/50), 52% (22/42) respectively. Patients with MRP-positive tumours had shorter survival time than the MRP-negative patients significantly(P < 0.01). CONCLUSIONS: Adenocarcinoma had higher MRP expression than squamous carcinoma significantly, positive MRP immunostaining appears to be an independent indicator of poor prognosis in NSCLC.

Adult↗

PubMed1999

[Clinical study of anastrozole in the treatment of postmenopausal women with advanced breast cancer].

OBJECTIVE: To study the effect and adverse reactions of anastrozole in the treatment of postmenopausal women with advanced breast cancer. METHODS: A multicenter, open, non-randomized and crossover clinical trial on the effect of anastrozole was conducted. Sixty-one postmenopausal women with advanced breast cancer were treated by oral anastrozole, 1 mg once every day. Each patient received 4-6 weeks of treatment. Plasma estradiol concentrations were determined 2 weeks before treatment and within 3 days after treatment discontinued. Effect and adverse reaction were evaluated. RESULTS: The response rate in 60 evaluable cases treated with anastrozole was 21.7% (CR = 0, PR = 13, MR = 2). The effect was correlated with postmenopausal time, previous endocrine therapy and ER status. Plasma level of estradiol was suppressed by 58.3%. The main adverse reactions, including nausea, fatigue, facial flush, were generally tolerable. CONCLUSION: As an aromatase inhibitor capable of decreasing plasma estradiol level, anastrozole is therapeutically effective for advanced breast cancer in postmenopausal women. Side effects are mild and tolerable.

Adult↗

PubMed1999

[Expression of multidrug resistance-associated protein (MRP) and lung resistance protein (LRP) in human rectal carcinomas and its clinical significance].

OBJECTIVE: To investigate the expression and clinical significance of multidrug resistance-associated protein(MRP) and lung resistance protein(LRP) in rectal carcinoma. METHODS: Fiftyseven paraffin embeded primary rectal carcinoma specimens were examined by immunohistochemical staining. RESULTS: Of the 57 tumour specimens examined, 28(49.1%) and 24(42.1%) were positively immunostaned for MRP and LRP, respectively. Co-expression of the two proteins was observed in 10(17.5%) specimens. Positive immunostaning of either of the two proteins was not correlated with cell differentiation and Dukes stage (P > 0.05). Patients with MRP-positive tumours had shorter survival than MRP-negative patients (P < 0.05). No such correlation was found for LRP expression, nor was found between MRP and LRP expression. CONCLUSION: Positive MRP expression in rectal carcinoma appears to be an independant factor of prognostic significance. To examine its expression may help guide rational comprehensive therapy of rectal carcinoma.

Adult↗

PubMed1999

[Mitomycin, vindesine and cisplatin combination therapy in the treatment of advanced non-small cell lung cancer: a report of 108 cases].

OBJECTIVE: To evaluate the results of combination chemotherapy with mitomycin (MMC), vindesine (VDS) and cisplatin (DDP) in patients with advanced non-small cell lung cancer (NSCLC). METHODS: A total of 108 patients with advanced NSCLC was enrolled in this study. Adenocarcinoma (74 cases) and squamous-cell carcinoma (23 cases) were the most common type of malignancy. Thirty patients received prior chemotherapy while 78 did not. RESULTS: Complete response was observed in 1 patient and partial response in 36 patients with an overall response rate (RR) of 34.3%. The RR was significantly higher in the previously untreated patients (41.0%) and than that in the pretreated patients (P = 0.0169). The RR did not significantly differ between patients with squamous--cell carcinoma (30.4%) and adenocarcinoma (32.4%). That of patients with metastases to the lymph nodes, to the other parts of lung, liver and bone was 43.1%, 32.4%, 25.0% and 0, respectively. The median response duration was 3 months and the median survival period was 7 months. The dose limiting toxicity was neutropenia, which was in grade III and IV in 41.7% of the treated patients. Grade III and IV thrombocytopenia was observed in 6.5% and grade III and IV nausea and vomiting in 21.3% of the treated patients. CONCLUSION: A higher response rate is attainable in patients with advanced NSCLC treated by MMC, VDS and DDP with tolerable toxicity.

Adult↗

PubMed1999

[Phase II clinical study of a new anticancer drug boanmycin].

OBJECTIVE: To evaluate the efficacy of boanmycin (BAM) in patients with advanced cancers. METHODS: A multicenter phase II clinical study on BAM was conducted on 105 cases received BAM as single agent, and 220 cases were treated with combination chemotherapy containing BAM. RESULTS: The total response rate was 35.0% for single agent and 64.2% for combination chemotherapy group in advanced cancers. The response rate for single agent in malignant lymphoma, cancer of head and neck and breast cancer was 66.7%, 65.0% and 37.5%, respectively; and for combination chemotherapy group in malignant lymphoma, breast cancer, head and neck cancer, esophageal cancer and lung cancer was 88.5%, 62.5%, 50.0%, 47.2% and 45.8%, respectively. The main side effects with mild or moderate fever, chill, myalgia, gastrointestinal reactions, skin pigmentation as well as hardening of skin at injection site. CONCLUSIONS: BAM therapy was effective in malignant lymphoma, cancer of head and neck and other cancers.

Adolescent↗

PubMed1998

Detection of mouse osteopontin by western blotting.

Several different antibodies to mouse and/or rat osteopontin have been developed, and some antisera raised against human osteopontin have been shown to react with mouse osteopontin. We have taken advantage of the lack of osteopontin protein in mice with a targeted disruption of the osteopontin gene to characterize the reactivity and the specificity of several of these antibodies with mouse osteopontin by Western blotting. Our results demonstrate that, with the exception of the rat monoclonal antibody MPIIIB10, which does not recognize mouse osteopontin on Western blots, all the tested reagents do react with mouse osteopontin, but their sensitivity varies widely, and in some cases there is significant cross-reactivity of the antibodies with other proteins found in mouse tissue extracts.

Animals↗

PubMed1998

Electrical impedance tomography reconstruction algorithm based on general inversion theory and finite element method.

A strict EIT reconstruction algorithm, the general inversion algorithm (GIA) is presented. To improve the noise performance, the algorithm is modified by attenuating the condition number of the forward matrix F and implemented using an improved FEM scheme, to obtain the 2D image of impedance change (dynamic image). This modified general inversion algorithm (MGIA) can be used on a larger dimension FEM model (248 elements) and is more practical than the GIA. When implementing this algorithm in computer simulation and in a physical phantom, it is found that the MGIA has a smaller reconstruction error than the currently used algorithms (equipotential-back-projection algorithm and filtered spectral expansion algorithm). With 0.1% white noise in the data, the algorithm can still reconstruct images of a complicated model. Further improvements are also discussed.

Algorithms↗

PubMed1998

Comparison of radiography, computed tomography and magnetic resonance imaging in the detection of sacroiliitis accompanying ankylosing spondylitis.

OBJECTIVE: To compare magnetic resonance (MR) imaging, computed tomography (CT), and radiography in the detection of sacroiliitis accompanying ankylosing spondylitis (AS). DESIGN AND SUBJECTS: Nine volunteers and 24 patients were recruited. Radiography, CT, and MR imaging were completed within a 1-week period in 24 patients with AS. In precontrast MR examination, spin-echo T1, fast spin-echo T2, and gradient echo with rephasing T2* images were obtained without fat saturation using a 0.3-T imager for all volunteers and patients. Postcontrast MR examination was performed using the same precontrast SE T1 sequence for patients with AS. RESULTS AND CONCLUSIONS: MR imaging directly showed the normal cartilage in all 16 sacroiliac joints of the 8 volunteers. In the 24 patients with AS, cartilage abnormalities were observed in 42 sacroiliac joints. More diagnoses of sacroiliitis were made using MR and CT imaging than using radiography (P < 0.001). Therefore, low-field-strength MR can be useful in detecting early sacroiliitis in patients with AS. MR imaging was able to reveal early cartilage changes and bone marrow edema, which could not be found by either CT or radiography.

Adolescent↗

PubMed1998

Association of a serotonin transporter gene promoter polymorphism with harm avoidance behaviour in an elderly population.

A polymorphic 44-nucleotide insertion/deletion in the promoter region of the serotonin transporter gene (5-HTTLPR) has been shown to affect the level of expression of the serotonin transporter protein. An association between anxiety-related behavioural traits and the short form of the 5-HTTLPR has been reported. We determined the 5-HTTLPR genotype in genomic DNA samples from 84 subjects (47 Parkinson's disease patients and 37 controls) with a mean age of 67.4 years. The TPQ of Cloninger was used to obtain values for harm avoidance (HA), reward dependence and novelty seeking for all subjects. Analysis of variance showed a significant influence of the s-allele of the 5-HTTLPR on HA in both subject groups, with no significant interaction between diagnosis and genotype. Subjects with the l/l-genotype had significantly lower mean HA scores than the l/s subjects (P < 0.04) and s/s subjects (P < 0.003). A linear change in HA with genotype was observed, indicating a gene dose effect of the 5-HTTLPR s-allele on this personality dimension. Based on these findings it is suggested that there may be increased influence of the 5-HTTLPR short allele on anxiety-related traits during aging.

Aged↗

PubMed1998

Association of long variants of the dopamine D4 receptor exon 3 repeat polymorphism with Parkinson's disease.

The dopamine D4 receptor (D4DR) has a highly polymorphic region in the third exon which has been associated with novelty seeking (NS) behavior. Due to the central position of dopamine and the documented low NS in Parkinson's disease (PD), the frequency of the exon 3 variants of D4DR in 95 PD patients and 47 controls was investigated. A significantly higher frequency of exon 3 alleles with six or more repeat units was found in the PD group (p = 0.039). This provides evidence that some forms of the highly polymorphic D4DR may represent a genetic susceptibility factor for PD.

Adult↗

PubMed1998

[Randomized controlled study of leucomax (recombinant human granulocyte-macrophage colony stimulating factor, rhGM-CSF) in the treatment of cancer chemotherapy-induced leucopenia].

OBJECTIVE: To evaluate leucomax (rhGM-CSF) in prevention and treatment of leucopenia and neutropenia induced by chemotherapy in cancer patients. METHODS: A multicenter, randomized, matched and cross-over clinical trial of the effect of leucomax on leucopenia and neutropenia induced by combination chemotherapy in cancer patients was conducted. Fifty seven enrolled patients were randomized into AB group and BA group. Each patient received two cycles of treatment. In group AB, combination chemotherapy and leucomax were used in the first cycle and combination chemotherapy alone was used in the second cycle, while vice versa in group BA. In 2 patients, the study was stopped due to leucomax adverse reactions. Fifty five patients were eligible for analysis of clinical efficacy. RESULTS: Leucomax significantly increased the number of total white blood cell count and absolute neutrophil count at the nadir, decreased the incidence of leucopenia and neutropenia and shortened the time period of leucopenia and neutropenia induced by chemotherapy. Leucomax also resulted in quicker recovery of leucopenia and neutropenia. Leucomax ensured the scheduled chemotherapy. The main adverse reactions with mild to moderate fever, pain at the injection site, bone pain, myalgia, asthenia and skin rash were generally tolerable. CONCLUSION: Leucomax is a valuable adjunct in cancer chemotherapy.

Adult↗

PubMed1998

[Molecular cloning and DNA sequencing of OspC gene of two strains Borrelia burgdorferi isolated in China].

OBJECTIVE: To investigate the variation of OspC gene in two Chinese isolates of Borrelia burgdorferi. METHODS: PCR technique was used to amplify the OspC gene from the whole cellular DNA of isolates BT01 and BJ-9011. The amplified products were inserted into plasmid pGEM-3ZF(+) and sequenced. RESULTS: Except the signal peptide, the OspC genes of the two isolates BT01 and BJ-9011 were 579 bp and 576 bp which encode 193, 192 amino acids respectively. The nucleotide and amino acids sequence identity between the two strains was 86% and 83%. High homology exists between these Chinese isolates and several foreign isolates (PBi, PKo, B31), especially in BJ-9011. It had 99% nucleotide and amino acid sequence identified with B31. CONCLUSION: Variations in OspC genes are noted between the two Chinese Borrelia burgdorferi isolates and foreign isolates.

Antigens, Bacterial↗

PubMed1997

Subtype-specific intracellular trafficking of alpha2-adrenergic receptors.

The three alpha2-adrenergic receptor subtypes (alpha2a, alpha2b, and alpha2c) are highly homologous G protein-coupled receptors. These receptors all couple to pertussis toxin-sensitive G proteins and have relatively similar pharmacological properties. To further explore functional differences between these receptors, we used immunocytochemical techniques to compare the ability of the three alpha2-receptor subtypes to undergo agonist-mediated internalization. The alpha2a-receptor does not internalize after agonist treatment. In contrast, we observed that the alpha2b-receptor is able to undergo agonist-induced internalization and seems to follow the same endosomal pathway used by the beta2-adrenergic receptor. Attempts to examine internalization of the alpha2c-receptor were complicated by the fact that the majority of the alpha2c receptor resides in the endoplasmic reticulum and cis/media Golgi and there is relatively little cell surface localization. Nevertheless, we were able to detect some internalization of the alpha2c-receptor after prolonged agonist treatment. However, we observed no significant movement of alpha2c-receptor from the intracellular pool to the plasma membrane during a 4-hr treatment of cells with cycloheximide, suggesting that these cells are unable to process alpha2c-receptors in the same way they process the alpha2a or alpha2b subtypes.

Amino Acid Sequence↗